Armata Pharmaceuticals, Inc. (ARMP) stock
ARMPNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.17+0.51 (+19.17%)
Close on Nov 18, 2026Market cap $117.87MP/E –Yield –
Armata Pharmaceuticals shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Armata Pharmaceuticals's shares outstanding was 62M at Jun 30, 2026. For fiscal 2025 it was 36M, down 38.6% from the year before. Over ten years it grew 85.0% a year on average. The highest annual figure on record is 59M in fiscal 2024.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 36M | -38.6% |
| FY2024 | Dec 31, 2024 | 59M | +63.7% |
| FY2023 | Dec 31, 2023 | 36M | +5.2% |
| FY2022 | Dec 31, 2022 | 34M | +42.3% |
| FY2021 | Dec 31, 2021 | 24M | +46.8% |
| FY2020 | Dec 31, 2020 | 16M | +104.9% |
| FY2019 | Dec 31, 2019 | 8M | +72.2% |
| FY2018 | Dec 31, 2018 | 5M | +395.4% |
| FY2017 | Dec 31, 2017 | 1M | +568.2% |
| FY2016 | Dec 31, 2016 | 0M | +81.8% |
| FY2015 | Dec 31, 2015 | 0M | -8.1% |
| FY2014 | Dec 31, 2014 | 0M | +190.8% |
| FY2013 | Dec 31, 2013 | 0M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 62M | +71.4% |
| Q1 FY2026 | Mar 31, 2026 | 37M | -38.6% |
| Q4 FY2025 | Dec 31, 2025 | 36M | +0.5% |
| Q3 FY2025 | Sep 30, 2025 | 36M | +0.1% |
| Q2 FY2025 | Jun 30, 2025 | 36M | -37.9% |
| Q1 FY2025 | Mar 31, 2025 | 59M | +64.6% |
| Q4 FY2024 | Dec 31, 2024 | 36M | +0.2% |
| Q3 FY2024 | Sep 30, 2024 | 36M | +0.3% |
| Q2 FY2024 | Jun 30, 2024 | 58M | +3.0% |
| Q1 FY2024 | Mar 31, 2024 | 36M | +0.2% |
| Q4 FY2023 | Dec 31, 2023 | 36M | +0.1% |
| Q3 FY2023 | Sep 30, 2023 | 36M | +0.1% |
| Q2 FY2023 | Jun 30, 2023 | 57M | +57.1% |
| Q1 FY2023 | Mar 31, 2023 | 36M | +24.3% |
| Q4 FY2022 | Dec 31, 2022 | 36M | +37.0% |
| Q3 FY2022 | Sep 30, 2022 | 36M | +45.2% |
| Q2 FY2022 | Jun 30, 2022 | 36M | +45.4% |
| Q1 FY2022 | Mar 31, 2022 | 29M | +41.7% |
| Q4 FY2021 | Dec 31, 2021 | 26M | +42.8% |
| Q3 FY2021 | Sep 30, 2021 | 25M | +34.9% |
| Q2 FY2021 | Jun 30, 2021 | 25M | +35.0% |
| Q1 FY2021 | Mar 31, 2021 | 20M | +95.7% |
| Q4 FY2020 | Dec 31, 2020 | 18M | +93.1% |
| Q3 FY2020 | Sep 30, 2020 | 18M | +92.6% |
| Q2 FY2020 | Jun 30, 2020 | 18M | +137.6% |
| Q1 FY2020 | Mar 31, 2020 | 10M | +124.6% |
| Q4 FY2019 | Dec 31, 2019 | 10M | +105.2% |
| Q3 FY2019 | Sep 30, 2019 | 10M | +105.3% |
| Q2 FY2019 | Jun 30, 2019 | 8M | +65.9% |
| Q1 FY2019 | Mar 31, 2019 | 5M | +144.9% |
| Q4 FY2018 | Dec 31, 2018 | 5M | +234.4% |
| Q3 FY2018 | Sep 30, 2018 | 5M | +267.0% |
| Q2 FY2018 | Jun 30, 2018 | 5M | +490.0% |
| Q1 FY2018 | Mar 31, 2018 | 2M | +692.7% |
| Q4 FY2017 | Dec 31, 2017 | 1M | +626.5% |
| Q3 FY2017 | Sep 30, 2017 | 1M | +698.1% |
| Q2 FY2017 | Jun 30, 2017 | 1M | – |
| Q1 FY2017 | Mar 31, 2017 | 0M | – |
| Q4 FY2016 | Dec 31, 2016 | 0M | – |
| Q3 FY2016 | Sep 30, 2016 | 0M | – |
See a number that looks wrong?